Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.79USD
4:00pm EDT
Change (% chg)

$-0.02 (-2.36%)
Prev Close
$0.81
Open
$0.83
Day's High
$0.83
Day's Low
$0.79
Volume
185,862
Avg. Vol
122,948
52-wk High
$12.96
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

Trovagene Presents Outlook For Second Half Of 2018
Monday, 9 Jul 2018 08:00am EDT 

July 9 (Reuters) - Trovagene Inc ::TROVAGENE PRESENTS OUTLOOK FOR SECOND HALF OF 2018.TROVAGENE-PROVIDE PRELIMINARY SAFETY DATA ON COMBINATION OF PCM-075 + LDAC,COMBINATION OF PCM-075 + DECITABINE IN PATIENTS TREATED THROUGH END OF 2018.TROVAGENE INC - CONTINUE TO FOCUS ON ADVANCING OUR TWO ACTIVE CLINICAL TRIALS WITH PCM-075.TROVAGENE INC - LOOKING AHEAD TO SECOND HALF OF 2018, CO'S BOARD OF DIRECTORS IS UNDERTAKING A SEARCH FOR A NEW CEO.  Full Article

Trovagene Announces Leadership Change
Friday, 22 Jun 2018 05:19pm EDT 

June 22 (Reuters) - Trovagene Inc ::TROVAGENE ANNOUNCES LEADERSHIP CHANGE.TROVAGENE INC - WILLIAM WELCH HAS RESIGNED AS CEO AND DIRECTO.TROVAGENE INC - THOMAS ADAMS, CHAIRMAN OF BOARD APPOINTED INTERIM CEO.TROVAGENE SAYS WILLIAM WELCH HAS RESIGNED AS CEO AND DIRECTOR (FIXES TYPO).  Full Article

Trovagene Reports Q1 Loss Per Share $0.09
Tuesday, 8 May 2018 04:15pm EDT 

May 8 (Reuters) - Trovagene Inc ::TROVAGENE ANNOUNCES FIRST QUARTER 2018 HIGHLIGHTS AND FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.09.  Full Article

Trovagene Reports Q4 Loss Per Share $0.06
Monday, 26 Feb 2018 04:43pm EST 

Feb 26 (Reuters) - Trovagene Inc ::TROVAGENE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS.Q4 LOSS PER SHARE $0.06.  Full Article

Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1B/2 Acute Myeloid Leukemia Trial
Thursday, 21 Dec 2017 08:00am EST 

Dec 21 (Reuters) - Trovagene Inc ::TROVAGENE ANNOUNCES ACTIVATION OF SECOND CLINICAL TRIAL SITE IN PHASE 1B/2 ACUTE MYELOID LEUKEMIA (AML) TRIAL FOR PCM-075.TROVAGENE INC - ACTIVATION OF SECOND CLINICAL TRIAL SITE FOR ITS PHASE 1B/2 MULTICENTER TRIAL OF PCM-075 IN PATIENTS WITH AML.  Full Article

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®
Thursday, 14 Dec 2017 08:00am EST 

Dec 14 (Reuters) - Trovagene Inc ::TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.TROVAGENE INC - ‍LOOKING FORWARD TO A DECISION FROM FDA PERMITTING STUDY TO PROCEED, INITIATING MCRPC CLINICAL TRIAL IN PROSTATE CANCER IN 2018​.  Full Article

Trovagene Inc updates on clinical trial for PCM-075
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Trovagene Inc ::Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075.Trovagene Inc - ‍activation of its clinical trial site for its phase 1B/2 multicenter trial of PCM-075 in patients with AML​.Trovagene Inc - ‍trial will enroll subjects in phase 1B who have relapsed or have resistant disease to no more than three prior regimens​.  Full Article

TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12
Thursday, 9 Nov 2017 10:18am EST 

Nov 9 (Reuters) - Trovagene Inc ::Q3 LOSS PER SHARE $0.12.‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​.  Full Article

Trovagene files for offering of up to $17.5 mln- SEC filing
Wednesday, 25 Oct 2017 05:01pm EDT 

Oct 25 (Reuters) - Trovagene Inc : :Trovagene Inc files for offering of up to $17.5 million - SEC filing.  Full Article

Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075
Monday, 9 Oct 2017 08:00am EDT 

Oct 9 (Reuters) - Trovagene Inc :Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML).Trovagene - initiating Phase 1b/2 open-label trial to evaluate safety & anti-leukemic activity of PCM-075 in combination with standard-of-care in patients with AML​.  Full Article

BRIEF-Trovagene Completes First Dosing Cohort Of Patients In Phase 1B/2 Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF FIRST DOSING COHORT OF PATIENTS IN ONGOING PHASE 1B/2 TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage: